Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franchini, M
Right arrow Articles by Gandini, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franchini, M
Right arrow Articles by Gandini, G
Haematologica, Vol 88, Issue 11, 1279-1283
Copyright © 2003 by Ferrata Storti Foundation

Journal Article

Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease

M Franchini, G Rossetti, A Tagliaferri, C Pattacini, D Pozzoli, G Lippi, F Manzato, D Bertuzzo, and G Gandini

Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona,Verona, Italy. mfranchini@mail.univr.it

BACKGROUND AND OBJECTIVES: To evaluate the efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate-P as replacement therapy in patients with von Willebrand's disease (VWD) undergoing surgical or invasive procedures. DESIGN AND METHODS: Between January 1996 and October 2002, 26 patients (12 males and 14 females, median age 41.5 years, range 9-80 years), followed at three Italian Hemophilia Centers (Trento, Verona and Parma), with VWD type 1 (19 cases) and VWD type 2B (7 cases), underwent 43 surgical or invasive procedures: major surgery (14 cases), minor surgery (11 cases), dental extractions (11 cases), invasive diagnostic procedures (7 cases). Replacement therapy with factor VIII/von Willebrand factor concentrate (Haemate-P) was administered in the surgical setting as perioperative prophylaxis against excessive bleeding. RESULTS: The mean total dose (range) of Haemate-P used for major surgery was 284.1 IU VWF:RCo/kg (range 125.0-976.4), for minor surgery it was 120.8 IU VWF:RCo/kg (range 42.9-173.3), for dental extractions it was 38.4 IU VWF:RCo/kg (range 23.5-100.0) and for invasive procedures it was 87.3 VWF:RCo/kg (range 27.3-160.0). We recorded one bleeding episode 3 days after multiple dental extractions in a patient with severe periodontal disease; this bleeding was controlled with 2 further administrations of concentrate. We did not observe thrombotic episodes or other side effects following infusion of the concentrate. INTERPRETATION AND CONCLUSIONS: In conclusion, Haemate-P was effective and safe in preventing excessive bleeding after major and minor surgery or invasive procedures in VWD patients.


This article has been cited by other articles:


Home page
 haematolHome page
A. B. Federici, G. Castaman, M. Franchini, M. Morfini, E. Zanon, A. Coppola, A. Tagliaferri, E. Boeri, M. G. Mazzucconi, G. Rossetti, et al.
Clinical use of Haemate(R) P in inherited von Willebrand's disease: a cohort study on 100 Italian patients
Haematologica, July 1, 2007; 92(7): 944 - 951.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2003 by the Ferrata Storti Foundation.